Introduction
The kidney receives an abundant blood flow of 25 %o fc ardiac output and eliminates xenobiotics and metabolic products from the blood into the urine. [1] Three processes in kidneysa re involved during the formation of urine, including glomerular filtration,t ubular reabsorption, and tubular secretion (Figure 1a) . [2] Glomerular filtration is essential for the kidney to remove waste products and toxins rapidly from the plasma. [3] The kidney tubules are responsible for reabsorption and secretion of substances to regulate plasma pH, potassium concentrations, and other physiological environment. [4] Renal damage in glomerular and tubular function affects the ability of the kidney to remove xenobiotics and metabolic products from the blood into the urine. [5] Thus, evaluation of kidney function is crucial foranumber of clinicalsituations.
Kidney disease or the loss of kidney function is often difficult to diagnosea ta ne arly stage butc an causel ethal kidney failure later on. Of note, differentiation of the stages of kidney dysfunction has been along-term challenge. Therefore, preclinical techniques that can readily stage kidney dysfunction are essential to understand the progression of kidney disease. Furthermore, acute renal failure (ARF) has numerous causes such as hypotension, sepsis,t rauma,a cute tubular necrosis, drug-induced nephrotoxicity,a nd urinary obstruction. [6] Identifying the disease culprits in ARF is difficult ando ften relies on renal biopsy.H owever,t his method is invasive andh as potential risks. [6] In vivo fluorescencei maging is an inexpensive, highly sensitive, and widely utilized preclinicalm ethodt hat is used to study various diseases.S ignificant developments in the area of diagnosing kidney function and disease on the basis of lightemitting agents and fluorescence imaging hasb een made in the past ten years. The aim of this Reviewi st od escribe:o ne, traditional agents and determination methods for the assessment of kidney function; two, the utilization of organic fluorescent agents for the noninvasive real-timea ssessment of kidney function; three, inorganic nanomaterials in combination with imagingt echnologies to identify varioust ypes of nephropathies and to differentiate the stageso fk idney dysfunction. The
The noninvasive assessment of kidney functiona nd diagnosis of kidney disease have long been challenges. Traditionalm ethods are not routinely available, because the existing protocols are cumbersome,t ime consuming, and invasive. In the past few years, significant progress in the area of diagnosing kidney functiona nd disease on the basis of light-emitting agents has been made. Herein, we briefly review light-emitting agents, including organic fluorescent agents and inorganic renal clearable luminescentn anoparticles for the noninvasive and realtime monitoring of kidney function and disease. Moreover, some significant requirements and strategies regarding the design of ideal glomerular filtration rate agents and renal clearable nanoparticles are discussed. Finally,w ed iscussf uture challenges in expediting clinical translation of these developed light-emitting agents, along with considerations of the efforts that need to be made to develop new agents and diagnosing kidney disease. [8] Reprintedw ith permissionf rom Ref. [8] .C opyright( 2016) American Chemical Society. main emphasis is placed on the design and application of light-emitting agents, including organic fluorescent agentsa nd inorganic nanomaterials as ameans to monitor kidney function and disease.
Traditional Agents and Determination Methods for the Assessment of Kidney Function
The functional state of the kidneys can be assessed by using the glomerular filtration rate( GFR), renal blood flow,a nd tubular reabsorption or secretion of variouss ubstances. [7] Among them, the GFR is often used to evaluate overall renal function and is accepted as the best indicator for kidney function. [8] The GFR represents the plasma volume cleared by the nephrons per time unit during urine formation.I ti sg enerally presented in milliliter per minute. [3] However, the GFR cannotb em easured directly.T he most common methodi sb ased on the concept of clearance. [4] The concentration of endogenous creatinine in plasma is commonly used to determine the GFR (Figure 1b) , but it may resulti ne rroneous estimates due to age, gender,m usclem ass, and many other anthropometric variables. [9] Determination of the plasma/urinaryclearance of exogenous renal agents such as 99m Tc -DTPA( diethylenetriaminepentaacetica cid, DTPA), inulin, and iothalamate ( Figure 1c )i si nvasive and cumbersome due to the requirement of multiple blood/urine sampling steps and tedious sample analysis by high-performance liquid chromatography (HPLC). [8] Moreover, many studies have revealed that creatinine and iothalamate are secreted by proximal tubule cells, whereas cystatin Ca nd 99m Tc -DTPAa re reabsorbed by the tubulare pithelial cells, which leads to ab ias in the GFR. [5] Urinary clearance is the traditional method to determine the GFR. However, timed urinary collections are time consuming,c umbersome, and susceptible to error.Along period of urine collection over 24 ht od etermine creatinine clearance is no longerr outinely recommended as am eans to assess kidney function. [5] Alternatively, plasma clearance is used to determinet he GFR to avoid inconvenience and to prevent errors from timed urine collections. Nevertheless, the main limitation of plasma clearance is the need for repeateda nd invasive bloods ampling. [4] Thus, new GFR agents and determination methods are highly desired to improve the determination of kidney function.
Organic Fluorescent Agents for Noninvasive Assessment of Kidney Function
Real-time, noninvasive assessment of the GFR is essential not only to monitor ill patients at bedside in clinics buta lso to diagnose and stage patients with chronic kidneyd isease. [10] Noninvasive in vivo imagingi ncluding single-photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), and computed tomography (CT) are widely used to assess kidneyf unction by real-timem onitoring of the kidney clearance kinetics of renal-clearable agents. [11] [12] [13] However, those techniques may result in erroneouse stimates, because traditional GFR agents are used and their reabsorption or secretion in proximal tubules is suspected. What is worse, the diagnosiso fk idney diseases has not been greatly improved with the use of those techniques, due to their high costs,low accessibility,a nd the potential risk of exposure to radiation. [12] Thus, novel noninvasive techniques are highly needed for the assessment of kidney function. To this end, the development of fluorescent agentsa nd detection methods has provided new strategies.H owever,o nly al imited number of fluorescent agents have so far been developed to assess kidney function ( Table 1) . for the real-time assessment of renal function by using nonradioactivem ethods. [10, 14] Twog eneral approaches fort he design of fluorescent renal agents have been considered. The first approachi nvolvese nhancingt he fluorescenceo fk nown or existing renal agents that are intrinsically poor emitters such as lanthanide-metal complexes;f or example, as eries of Eu 3 + and In 3 + complexes of DTPA-monoamide ligands bearing molecular "antennae" to enhance metal fluorescencet hrough an intramolecular ligand-metalf luorescencer esonance energytransfer process have been prepared and evaluated by fluorescence enhancement and biodistribution. Compound 18 a and 18 b (Figure 2a )e xhibit the highest fluorescent enhancement in those DTPA-type metal complexes. The kidney clearance properties can be assessedb yu sing the corresponding radioactive 111 In complexes.T oa ssess whether these complexes are reabsorbed or secreted by organic anion transporter (OAT) proteins in kidneyt ubules, probenecid, an inhibitor of OATp roteins, is administered (30 minp rior) to block both the tubular reabsorption and secretion pathways. However,t he results suggest that these complexes are excreted not only by glomerular filtration but also through secretion in the proximal tubules. [10] The other approachisb ased on transforming fluorescent lipophilic dyes into hydrophilic and anionic substances to force them to be eliminated by the kidneys. Thus, the pyrazine-dicarboxylic acid backbone (Figure 2a,c ompound 1a) i sl ipophilic and insoluble in water,a nd it can be used as af luorophore and can be modified at the 2,5-positions with electron-withdrawing groups and at the 3,6-positions with electron-donating groups to improvei ts wavelength properties. [14] By this concept, variousn eutral and anionic substituents have been designeda nd synthesized by condensing the pyrazine scaffold with amino ethanol, aminopropanediol, and amino acid derivatives. These pyrazine derivatives can be divided into two general categories:o ne, pyrazine derivatives bearing primary amino groupsw ith the wavelengthi nt he blue range of the spectrum (Figure 2b ,c ompounds 2a-e); two, N-alkylated pyrazines bearing electron-donatingg roups with the wavelength in the green region of the spectrum (Figure 2b ,c ompounds 2f-j). In vitro and in vivo studies show that pyrazine markers 2d, 2h,a nd 2j have low plasma protein binding (PPB < 7%), plasma clearance half-lives ranging from 20 to 30 min, high urine recovery,a nd are excreted by the kidneys.M ore importantly,r enal tubular secretioni sn ot as ignificant elimination pathway for these three compounds,w hich is testified by treatingw ith probenecid to block the OATpathway. [14] Extensive studies to developan ew class of pyrazined erivatives based on the poly(ethylene glycol)( PEG) moiety have also been conducted. [15] PEG is ah ydrophilic,n ontoxic, biocompatible polymer consisting of repeating ethylene oxide units. It was approved by the Food and Drug Administration (FDA) in 1990 for parenteral or topical administrationasacomponent of various cosmetics, foods, and drug-delivery systems. [16] Particularly,P EG is eliminated through the kidneys without accumulation in the body,w hereast he clearance rate is dependento nt he molecular weight. It has been reported that PEGylation can significantly influence the excretion pathway and clearance rate. For example, the clearance half-life increasesfrom 18 min to 1day if the molecular weight of PEG increasesf rom 6t o1 90 kDa, and PEG chains with molecular NR [e] only filtrationblood sampling [19, 20] FITC weights less than 6kDa have been provent ob ef iltered by the glomerulus and not reabsorbed by kidney proximal tubules. [16] These considerations have led to the investigation of as eries of PEGylated pyrazinec onjugates. For as ystematic study of the effect of the lengtho fP EG, PEG chains with different lengthsh ave been conjugated to the pyrazineb ackbone, whereas the total molecular weight of PEG for modification has been limitedt ol ess than 5kDa for free filtration. These conjugates can also be divided into two categories:o ne, pyrazine derivatives bearingp rimary amino groups with the wavelength in the blue region of the spectrum;t wo, N-alkylated pyrazines with the wavelength in the green region of the spectrum. Similarly,b oth in vitro and in vivo assays including fluorescencep roperties, PPB, urinary recovery of the injected dose, probenecid blockings tudies, and plasma clearancek inetics have been performed. PEGylatedp yrazine compounds 4d and 5c have very low PPB values (5 and 3%,r espectively), high urinary recovery values (96 and 97 %, respectively), and short plasma clearance half-lives (25 and 19 min, respectively)i n healthyr ats. These two compounds exhibit properties that are superior to those of iothalamate, which is an accepted standard for the measurement of the GFR. [15] In preclinical studies, as eries of in vitro and in vivo safety/toxicity studies have been performed with fluorescent agent 2d (Figure 2b) , including blood compatibility,m utation assay, chromosomal aberration assay,a nd several single-dose toxicitys tudies in rats and dogs to determineo verall toxicitya nd toxicokinetics. [17] Upon administering high doses of up to 200-300 times the estimated human dose, all animalss urvivet os cheduled sacrifice. No effects are found on body weight, food consumption, and ophthalmic observations, and no abnormala natomical pathology is observedb ye ither macroscopic or microscopice valuation of any organ or tissue.T he resultso ft hese initial toxicology studies suggest that the safety/toxicity profiles of compound 2d should be sufficient to begin af irst-in-human clinicals tudy. However, further nonclinical testing regarding biodistribution [10] b) Structures and optical wavelengths of pyrazine-basedfluorescent agents. [14] c) Structures and optical wavelengths of PEG-pyrazine conjugates. [15] ChemistryOpen and developmental toxicitys hould be completed before starting the first-in-human studies. [17] Indeed,t os implify the determination methodo fb lood sampling, Dorshow et al. have developed an optical monitoring apparatus for noninvasive opticalk idney function studies. [18] The principle briefly is that one ear lobe is glued flat to ag lass slide positioned approximately 2mmb eneath af iber optic bundle that records the fluorescence signal from at est fluorescent agent passing throught he ear.Al = 445 nm solid-state laser source is directed through ac hopper and into one leg of as ilica-bifurcated fiber optic bundle. After as hort time period of recording the baseline, af luorescenta gent is intravenously injectedi nto the rat, and the fluorescences ignal corresponding to plasma and tissue distribution and subsequent renal clearance of the fluorescent agent is determineda tt he ear.A lthought he kidney clearance of af luorescent agentc an be detected by this noninvasive optical method, anesthesia is required during the whole measurement and can cause ad ecrease in the GFR. [18] 3.2. FITC-Inulin/Sinistrin for NoninvasiveA ssessmentof Kidney Function Inulin,aninert, uncharged polymer of fructosewith amolecular weighto fr oughly5 000 Da fulfils all criteria of an exogenous agent andi sr egarded as the gold-standard GFR agent. The GFR can be determined by injecting inulin intravenously.G iven that inulin is neither reabsorbed nor secreted by kidney tubules after glomerular filtration, its excretion rate is directly proportional to the rate of filtration of water and solutes across the glomerular filter. [4] Inulin has been successfully labeled in its fluoresceini sothiocyanate-conjugated variant (FITC-inulin, Figure3a). [19] Its elimination kinetics are generally obtained by measuring the fluorescent values in plasma over as pecific period of time after bolus injection. [20] Although highly reproducible results are generally obtained from this assay and urine sampling is not required, repeated blood sampling is stressful to the animals. Furthermore, the FITC-inulin solution needs to be heatedt oe nhancei ts solubility and dia- lyzed to remove residual unbound FITC, which make the procedure cumbersome. [20] To overcomet he poor water solubility of FITC-inulin,F ITCsinistrin was developed by ao ne-step chemical-labeling reaction ( Figure 3a) . [21] Sinistrin, an inulin analogue, was introduced in 1963 as an alternative to insulin to determine renal function due to its better water solubility. [22] The better water solubility of sinistrin is attributed to its branched chemical structure rather than the linear structure of inulin. On the other hand, we have developed an oninvasive transcutaneous technique to determine the elimination kinetics of the fluorescent FITC-sinistrin agent on the basis of am iniaturized electronic device attached to the skin. [23] The smart transcutaneous device comprises light-emitting diodes that excite af luorescent agent and ap hotodiode that detectst he emission signalo ft he injected fluorescent agent. [23] [24] [25] The workflow of the transcutaneous assessment of kidney function contains three main steps: 1) Af luorescent agent solutioni si njected into an animal intravenously,a nd the agenti sd iffused from the vascular space into the interstitium, where it is excreted by the kidneys.
2) The device is attached to the skin of an animal before the fluorescent agent is injected so that ab aselinec an be recorded for as hort time period.The device enables the fluorescenta gent to be excited repeatedly within the interstitial space by blinking each second at the appropriate wavelength. After each flash, the fluorescencee mission of the fluorescent agenti sd etected and convertedi nto ad igital signal. These digital data are stored in an internal memory within the device.
3) The excretion half-life of the fluorescent agent can be calculated after transferring and processing the data. [25] Similarly to the plasma clearance kinetics,t he collected data are evaluated to extrapolate the excretion kinetics of the fluorescent agent.
Extensive studies on kidney functionb ym eans of FITC-sinistrin have been conducted in preclinical animal models, including variouss trains of conscious mice (Balb/c, C57BL/6, SV129, and C57BL/6), [26] Dahl salt-sensitiveh ypertensive rats, [27] and large speciess uch as dogs and cats. [28] This transcutaneous approach has been validated in different animal species andp rovides am ore precise estimation of the GFR due to numerous data points from the transcutaneous measurements rather than al imited number of data points from blood and urine sampling. In addition, because measurementsa re taken transcutaneously,t his method is independento fa nthropometric parameters. The miniaturized transcutaneous device enables GFR measurements to be performed in conscious animals withouta nesthesia, and thus, it is possible to avoid an anesthesia-related decrease in the GFR. [4] Nevertheless,b oth inulin and sinistrin suffer from their inherent limitations, such as high costs, limited availability,a nd sophisticated extraction and purificationf rom plant roots. Therefore, there is an unmet and long-standing challenge to develop novel fluorescent GFR agentsf or the noninvasive real-time assessment of kidney function.
Fluorescently LabeledCyclodextrin Derivatives for Noninvasive Assessmento fKidney Function
An ideal exogenous fluorescent agent for transcutaneous assessment of kidney functionshould meet certain requirements: one, absorption and emission wavelengths in the visible region,a nd more preferably in the near-infraredr ange;t wo, high hydrophilicity and very low or no PPB; [29] three, neutral or weakly charged characteristics;f our,n ot oxicitya nd no metabolism in vivo;f ive, no reabsorption and no secretion in the tubules and complete filtration by the glomerulusi nto the urine; [30] six, easy to produce with low costs. The reasont om aintain lowP PB is that binding to proteins generally influences the resulting pharmacokinetics, pharmacodynamics, and biodistribution in vivo. Moreover,t ubular reabsorptiona nd secretion may be either active or passive, depending on the particulars ubstance and the transporter system in the tubular cells, fore xample, organic anion transporter( OAT) proteins and organic cation transporter (OCT) proteins. Thus, weak, charged characteristics are desirable to prevent interactions with organic transporter proteins.I ti sn ecessary to take all of these characteristics into account for the rational design of aG FR agent. Bearing this in mind, we have successfully developed 2-hydroxypropylcyclodextrin (HPCD)-based fluorescent agents fort he transcutaneous measurement of kidney function. [8] Fluorescent HPCD-based agentsa re judiciously designed by combining the basic principle of renally cleared drugs and the knowledgeo facyclodextrin (CD)-based drug-delivery system.I nt his design,f irst, the introduction of HPCDs (including HPaCD, HPbCD, and HPgCD)i ncreases the hydrophilicity,d ecreases PPB, and accelerates the elimination for fluorescent agents. The main elimination route of HPCDs is dependento nt he route of administration. For both rat and dog, following oral administration, HPbCD is mainly excreted in the feces, whereas it is excreted by the kidneys after intravenous administration. HPbCD is well tolerated in animal studies (e.g. rats, mice, dogs, and rabbits) for both short-term and long-term studies. For humans,e xcretion is mainly by the kidneys. CDs are well tolerated in humans and have no adverse effects on the kidneys or other organs followinge ither oral or intravenous administration. [31] The merits of their nontoxicity resultedi nF DA approval more than ten years ago. [32] The reason for the utilization of HPCDs rather than CDs is that HPCDs not only have better water solubility than their native CDs, but they are also more stable to hydrolysis by a-amylases of either porcine or human origin. [33] Additionally,t heir narrow molecular weight distribution, low cost, and sufficienta vailability make them ideal backbones for GFR agents. [34] Second, fluorophores belonging to the xanthenef amily are employed to label the HPCDs (Figure 3b ). Besides FITC and fluorescein, the panel of xanthene fluorophores has been expanded to include fluorophores based on decarboxylated FITC, referred to as XITC, for systematic study of the different conjugation bonds and sites between the fluorophore and the HPCDs.O nt he basis of considerable empirical knowledge that anionic and neutrals ubstances are preferentially cleared through the renal system, [14] rhodamine-based dyes have not been selected as fluorophores to labelt he HPCDs due to the positivec harge of the nitrogen atoms of the anilinem oiety or the diethylaniline group. The three resulting categories of agents display different covalent conjugation bonds and net molecularc harges and are suspected to display differentp harmacokinetics and pharmacodynamics. All of the FITC-HPCDs exhibit very low PPB (< 8%), which is comparable to or even lower than that exhibitedb ys ome previousG FR agents, for example 51 Cr-EDTA( 12.2 %, EDTA = ethylenediaminetetraacetic acid) and 99m Tc -DTPA( 11 %). The extremely low PPB of the HPCD-based agents is attributed to conjugation of the hydrophilic HPCDs on the hydrophobic fluorophores, which increases their hydrophilicity and reduces nonspecific interactions with serum proteins. These agents have no significant cytotoxic effect in representative human renal cell lines by using the 3-(4,5-dimethyl-2-thiazoly)-2,5-diphenyltetrazolium bromide (MTT) assay.B y using the above transcutaneous technique, the plasma clearance curves and kinetic parameters of all the agents can be obtained.T he clearance half-lives of the HPCD-based agents either in the absence or in the presenceo fp robenecid follow the order HPaCD-based agents > HPbCD-based agents > HPgCD-based agents, suggesting the rate of elimination increasesw ith the increasing size of the HPCD. The clearance half-lives of the tested agentsa lso vary with the fluorophore scaffold used, for example, XITC-HPbCD > FITC-HPbCD > fluorescein-HPbCD. In the FITC-HPCD series, FITC-HPaCD and FITC-HPgCD both have slight tubular reabsorption because shorter clearance half-lives are observed in the presence of probenecid. Fluorescein-HPCDs exhibit ac learanceh alf-life that is significantly higherw ith probenecid treatment than withoutp robenecid treatment, which indicates that they are secreted in kidney tubules. In contrast,F ITC-HPbCD andX ITCHPbCD display no tubular reabsorption or secretion and are cleared by glomerular filtration alone. Am andatory prerequisite for an ideal renal function agent is that it can obtain complete urinary recovery of the injected doses (IDs) and that it has no metabolism in vivo. Four agents, including FITCHPaCD,F ITC-HPbCD,F ITC-HPgCD,a nd XITC-HPbCD, have high urinary recoveries of nearly 100 %o ft he IDs and do not undergo metabolism in vivo. However,o nly 40 to 60 %o fthe IDs of fluorescein-HPCD is recovered in urine. These results suggest that fluorescein-HPCDsa re not completely excreted through the kidneys but also by other routes, including metabolism by enzymes in vivo. In sum, FITC-HPbCD is considered ap romising novel exogenous fluorescent GFR agent. Of note, premature death and adverse clinicals igns, as determinedb y measuring the body weight and food consumption of rats, are not observed during the entire set of experiments.
One of the major obstacles encountered with noninvasive real-time transcutaneous assessment of kidney functioni nvivo upon using the aforementioned fluorescent GFR agents is strong intrinsic background autofluorescence from livingt issue because of their short emission wavelength in the blue and green regions of the spectrum( l < 600 nm), which significantly compromises the accuracy of the measurements under physiological conditions. However,t he absorption coefficient of tissue in the near-infrared (NIR) region (l = 650-900 nm) is greatly suppressed to am inimum level, which thus drastically reduces the disturbancesa nd noise from autofluorescence and increases tissue penetration. [35] Therefore, it is highly desirable to develop GFR agents in the NIR optical window for transcutaneous assessment of kidney function. Recently,s everal studies have revealed that conventional organic fluorophores can persistently accumulate in the lipid membranes of the skin after intravenous injection because of their high lipophilicity. [36] The large hydrophobic p-conjugated systemso fo rganic NIR dyes generally lead to strong binding betweend yes and proteins in serum;f or example, indocyanine green (ICG, Figure 4a ) displays extremely high PPB (99 %), liver uptake, and excretion. Such ah igh PPB hampers its kidney excretion.M any attempts have been made to overcomet hese obstacles, and enhanced hydrophilicity and decreased PPB for someh eptamethine cyanine dyes can be achieved by increasing the number of sulfonate groups on the cyanined yes. [37] For example, the PPB of the commercial anionic dye IRDye800CW (Figure 4a )i sa sh igh as 41 %. Although kidney clearance of IRDye800CW can be determined by multispectralo ptoacoustic tomography( MSOT), [38] its plasma clearance curvesh ave no decay at 90 min postinjection upon using transcutaneous measurements. [35] These studies further confirm that rapid accumulationa nd long retention of conventional organic fluorophores in the skin is ad ilemma for the noninvasive transcutaneous measurement of renal function.
Recently,C hoi et al. reportedp ioneering work on zwitterionic heptamethine cyanine dyes. [39] Zwitterionic dyes with an eutral overall chargee xhibit reduced lipophilicity and PPB due to charge shielding.A ll zwitterionic analogues are excreted from the body into urine by kidney clearance with almost no significant nonspecific uptake into other organso rt issues. [40] Althought hese zwitterionic analogues have decreased PPB and can be completely cleared by the kidneys,t heir PPB is still higher than that of "gold-standard" renal function agents such as inulin and iothalamate (9.5 %) [35] and cause ar elatively long clearance half-life. Inspired by that work, we have reported the first NIR GFR agents with improved hydrophilicity and much lower PPB (< 7%)t hrough introducing zwitterionic charges and HPbCD on heptamethine cyanined yes. To study the influence of different molecular surfaces charges on their PPB and excretion systematically, NIR fluorescent agents with three different molecular surface charge characteristics (i.e. zwitterionic, anionic, and cationic;F igure 4b)h ave been designed, and they comprise two key functional components:H P bCD and NIR fluorophores. Covalentc onjugation between HPbCD and the NIR fluorophores is achieved by either ester bond or click chemistry.T heir spectra effectively match the configurationo ft he transcutaneous device, which consists of two light-emitting diodes with an excitation wavelength at 700 nm and ap hotodiode for emissionw avelength detection at 790 nm. In in vitro studies, the zwitterionic agentsA BZWCY-HPbCD and AAZWCY-HPbCD have much lower PPB (3.7a nd 6.5 %, respectively) than the anionic agents (i.e.A BANCY-HPbCD and AAANCY-HPbCD, 19.7 and 26.8 %, respectively) and the cationic agents( i.e. ABCACY-HPbCD and AACACY-HPbCD, 23.5 and 27.4 %, respectively), and even lower than some "gold-standard" agents. In vivo, urinary recovery and fluorescent distribution investigationsb ys mall-animali maging experimentsd emonstrate that both ABZWCY-HPbCD andA AZWCY-HPbCD can be completely andr apidly excreted throught he kidneys. Examinationo fu rine samples by HPLC and matrix-assisted laser desorption/ionization( MALDI) provest hat these two zwitterionic HPbCD-based agentsh ave no metabolism in vivo. These two zwitterionic HPbCD-based agents can be excreted efficiently through the kidneys into the urine without reabsorption ands ecretion in the tubules (Figure 5) , as evidencedb y studies on theb lockingo fb oth the OATand OCT proteins in kidneyt ubules by treating with probenecid and cimetidine, respectively.S tudies in transgenic nephropathy rat models also show that zwitterionic HPbCD-based agents are promising agentsf or evaluation of kidney function. Relyingo nt hese novel zwitterionic NIR agents and at ranscutaneous device, ar apid, robust, and biocompatible approachi sv alidated for assessing kidney function in rat models that are both healthy and with kidney diseasew ithout the need for time-consuming blood/urine sample preparation. Figure 4 . Structures of commercial cyanine dyes (ICG and IRDye800CW), zwitterionic cyanine dyes (ABZWCY and AAZWCY), and HPbCD-based NIR agents. [35] Reprinted with permission from Ref. [35] .Copyright( 2017) RoyalS ociety of Chemistry. 
Inorganic Nanomaterials for Identifying Various Types of Nephropathies and Differentiating the Stages of Kidney Dysfunction
Numerous nanoparticle( NP)-based agents have been utilized for biological and biomedical applications. The diverse research and applications of NPs have provided new strategies for monitoring kidney function and disease. Here, we describe both nonrenal-clearable and renal-clearable NPs for identifying kidney disease and monitoring kidney function, and especially, we summarize the strategies used to design renal-clearable NPs and the growing field of renal-clearable NPs for diagnosing variouskidney diseases.
Nonrenal-Clearable NPs for the Noninvasive Identification of Kidney Disease
Differentiation of kidney disease has long been ac hallenge, and currently,i to ften relies on renal biopsy.H owever,t his methodi si nvasive and has the potentialr isk for complications. [41] Macrophage activity occurs frequently in nephritis, renal transplant rejection,a nd renal obstruction, but it is generally absent in normal kidneys. [42, 43] Hauger et al. have used ultrasmall superparamagnetic iron oxide (USPIO) combined with MRI to determine if macrophage activity can be imaged and localized to compartmentso ft he kidneys on the basis of disease type. [44] In this study,amodel of nephrotoxic nephritis induced by meanso fi ntravenous injection of sheep antirat glomerular basement membrane serum and am odel of obstructive nephropathy are established. USPIO coated with dextran is injected into these two experimental rat models.I nt he nephrotoxic nephritis model, as ignificant decrease in the intensity of the MRI signal is observed only in the cortex,i nw hich the glomerular lesions are located at 24 hp ostinjection of USPIO. In the obstructive nephropathy model, ad ecrease in the intensity of the MRIsignal is found in all kidney compartmentsinresponse to diffuse interstitial lesions. The decrease in the intensity of the MRI signal is attributed to USPIO uptake by either macrophages or mesangialc ells. Furthermore, the decreased signal intensity is correlated to the degree of proteinuria in the nephritis model, which suggests that USPIO-enhanced MRI may help to identify and differentiate varioust ypes of nephropathies. [44] Inspiredb yt his study,J oe tal. have investigated if USPIO-enhanced MRI could also detecti nflammationi ni schemic acute renal failure. [45] The signal intensity in the outer medulla decreases after 24 and4 8hof ischemia, whereas it is not found in normal animals. USPIO is found inside the lysosomes of macrophages.I mportantly,t he change in the intensity of the MRI signal in the outer medullai sc orrelated with serum creatinine. USPIO injection does not alter renal function in both normal and ischemic animals.
Ta bata et al. have designed fluorescent silica nanoparticles (SiNPs) for inflammationi maging in am ouse model with acute interstitial nephritis and unilateral ureteral obstruction (UUO). Unilateralr enal obstruction has been found to cause an increasei nt he collagenous fibrous tissue in the renal interstitium after 6days from time of injury. [46] This change is able to be visualized with the assistance of fluorescent anti-CD11b SiNPs (CD11b is expressed on the surfaceo fm ouse macrophages). [47] After intravenous injection of fluorescent antiCD11b orientedly immobilized SiNPs to the mouse model with acute interstitial nephritis and UUO, the fluorescenta nti-CD11b orientedly immobilized SiNPs are accumulatedt oagreater extenti no ne kidney of the UUO model than in the normal and noninflamed kidneys. These findings are consistentw ith the histological resultst hat the fluorescent anti-CD11b orientedly immobilized SiNPs are associated with infiltration of macrophages into the inflammations ite. [47] Although these NPs are availablet oi dentify various types of nephropathies, their nonrenal-clearable feature may cause long-term retention in the organs of the reticuloendothelial system (RES) and may induce potentialtoxicity.
Renal-Clearable NPs for the NoninvasiveDifferentiation of the Stages of Kidney Dysfunction

Strategies for Designing Renal-Clearable NPs
The FDA has demanded that diagnostic agents injected into the human body be excreted completely within ar easonable amount of time. [48] Although NP-based agents show promising biomedical imaging and diagnostic features, toxicityi nduced by their nonspecific accumulationi nvivoi nt he organs of the [ 35] Reprinted with permission from Ref. [35] .C opyright (2017)Royal Societyo fChemistry. RES remains the primary roadblock to clinical translation. To avoid long-term toxicity and nonspecific accumulation, efforts have been made to accelerate the elimination of NPs. Generally,r enal excretion is ad esirable pathway for the elimination of NPs, because contrasta gentsc an be rapidlye liminated. Renal excretionr elies on glomerular filtration in the kidneys. [16] However,w hether an anoparticle can be cleared through the kidneys is highly dependent on its size, charge,a nd shape. [49] As shown in Figure 6 , the glomerular capillaryw all mainly includes the endothelium with fenestration (70-90nm), the glomerular basementm embrane (2-8 nm) , and the epithelium with af iltrations lit embedded into podocyte extensions (4-11 nm). Owing to the combined effects of each layer of the glomerular capillary wall, the filtration-size threshold of the glomeruli capillary wall is typically ah ydrodynamic diameter (HD) of 6-8 nm, [16] andt hus, kidney excretioni se xclusively possible for substances that are ultrasmall in size.
In 2006, renal excretion of inorganic materials was first observed by Kostarelos et al. in single-walled carbon nanotubes (SWCNTs). In this work, water-soluble SWCNTsa re functionalized with the chelating DTPAm oiety and are labeled with indium ( 111 In) for imaging. [50] Although these functionalized SWCNTsh avea na verage diameter of 1nma nd an average length of 300-1000 nm, they are not retainedi na ny of the organs of the RES and are rapidlyc leared from systemic blood circulation through the kidney excretion route. [50] Choi et al. reported pioneering work on renal-clearable quantum dots (QDs) in 2007. As eries of small QDs (Figure 7a )c omprising aC dSe core/ZnS shell and coated with different charged moieties on the surface, including anionic (e.g. dihydrolipoic acid), cationic (e.g. cysteamine), zwitterionic (e.g. cysteine), and neutral smallm olecules (e.g. dihydrolipoic acid connected PEG), have been synthesized. This is the first study reporting that QDs with aH Dl ess than 5.5 nm and az witterionic surface charge can be cleared through the kidneys. [48] Since these first two landmark reports,a ni ncreasing amount of renal-clearable NPs have been prepared (Table 2) , including SiNPs, [51] carbon dots, [52] iron oxide NPs, [53] palladium nanosheets, [54] copper nanoparticles (CuNPs), [55] and gold nanoparticles (AuNPs). [56] Urinaryr ecovery of these injected renal-clearable inorganic NPs with values higher than 50 %i so bserved in 24 h; this value is comparable to the renal-clearance efficiencies of some small molecular probes used in the clinic. Kidney accumulationo f these renal-clearable inorganic NPs is generally below 12 %o f the ID per gram of tissue at 24 hp ostinjection,w hich is comparable to or even lesst han that of nonrenal-clearable NPs in the range of 0.7 to 22 %o ft he ID per gram of tissue at 48 h postinjection. [57] In addition, an ew generation of SWCNTsh as been developed (Figure 7b ), and these SWCNTsa re functionalized with two fluorescent dyes (i.e. Alexa Fluor 488 and Alexa Fluor 680)a nd metal-ion chelates (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, DOTA) radiolabeled with 86 Yf or fluorescent and positrone mission tomography imaging, respectively.These SWCNTsa re rapidly renally cleared by glomerular filtration,a nd 65 %o ft he SWCNTsi so bservedi nt he urine. Importantly,c ompetitive inhibition of the OAT, OCT,a nd megalin-transport systemsi nt he tubulesd oes not affect clearance of the construct, whichr ules out tubular active secretion or reabsorption by these transporters as components of renal excretion. [58] These inorganic nanomaterials with efficient renal excretion share some significant features and strategiesf or designing renal-clearable NPs. 1) Size:T he size of the filtration threshold of the glomerular capillary wall is typically 6-8 nm;t herefore, reducing the size of the NPs is ap rimary strategy to enhance their renal- [58] c) InAs(ZnS) QDs with as ystematicincrease in the PEG chain length attached throughaDHLA linker. [62] ChemistryOpen 2017, 6,456 -471 www.chemistryopen.org 2017 The Authors. Publishedb yWiley-VCH Verlag GmbH &Co. KGaA, Weinheim clearance efficiency.W itht he helpo fi norganic synthetic chemistry,m ost inorganic nanoparticles with ac ore size below 6nmc an readily be prepared. 2) Shape: The efficient renal clearance of SWCNTsi nvolves as hape effect.A lthought he molecular weights (300-500 kDa) anda verage lengths (300-1000 nm) of SWCNTs are much largert han the molecular-weight cutoff( 50 kDa) and filtrationt hreshold (6-8 nm) for glomerular filtration, theseS WNTsc an still efficiently pass through the kidneys into the urine. This phenomenon can be explained by flowinduced orientation, which makes the long axis of the SWNTsp oint towardt he gap of the glomerular capillary pores. [57] Generally,r enal-clearable NPs have as pherical shape, ands phericalN Ps with ad iameter smaller than the kidney filtration threshold can be easily cleared into the urine. 3) Surface chemistry:N Ps with ultrasmall HDs are expected to cleart hrough the kidneys. However,m anyu ltrasmall NPs are still nonrenal clearable and are accumulatedi nt he organso ft he RES. For example, low urinaryr ecovery with av alue of only 9% of the ID has been determined for AuNPs coated with bis(p-sulfonatophenyl)phenylphosphine, whereas more than 50 %o ft he ID of these AuNPs is found in the liver at 24 hp ostinjection. Besides,C hoi et al. have also demonstrated thatQ Ds coated with anionic dihydrolipoic acid or cationic cysteamine have as mall HD (4 nm) and cannot be cleared through the kidneys and are mainly retained in the liver,l ung, and spleen. [48] The severe accumulation of ultrasmall NPs in the organs of the RES is attributed to protein adsorption,b ecause as ar esult of the high surface energy and charged ligands on the NPs, nearly thousands of different kinds of plasma proteins in the bloodc an interact with the surfaces of the particles if the NPs are distributed in the bloodstream. [59] Adsorption of those proteins can result in ar emarkable increase in their HD and their uptake in the organs of the RESb ym acrophages. [60, 61] To minimize serum protein binding, zwitterionic ligands( e.g. cysteine) and neutrall igands (e.g. PEG) have been used to modify the surfaces of NPs. More than 50 % of the ID of QDs coated with the zwitterionic cysteine ligand (HD:4 .9 nm) can be effectively cleared into the urine, and lesst han 5% of the ID is observed in the liver. [48] Unlikez witterionic ligandsw ith charged features and low molecular weights, PEG is am acromolecule with al ow charged ensity;t hus, inorganic NPs coated with PEG ligandsg enerally have much thicker stern layers than NPs coated with zwitterionic ligands, which often leads to aH D that is larger than the kidney filtration threshold. Nevertheless, investigations have revealed that inorganic NPs coated with short PEG chains are renal clearable with ah igh clearance efficiency. (Figure 7c ). [62] Furthermore, other inorganic renal-clearableN Ps coated with low-molecular-weight PEG (500-2000 Da) have been developed, such as PEG 500 -coated SiNPs, PEG 1000 -coated 5.5 nm, molecular weight of PEG:1kDa) [63] and GS-AuNP (cores ize:2 .5 nm, HD:3.3 nm). [67] ChemistryOpen 2017, 6,456 -471 www.chemistryopen.org 2017 The Authors. Publishedb yWiley-VCH Verlag GmbH &Co. KGaA, Weinheim AuNPs (Figure 8) , [63] and PEG 1500 -coatedc arbon dots. [52] These results indicatet hat fine controlo ft he PEG chain with an optimizedl ength is critical for developing renalclearable PEGylated NPs.
Renal-Clearable NPsfor the Noninvasive Staging of Kidney Dysfunction
Although zwitterionic-cysteine-coated QDs can be rapidly cleared into the urine (75 %o ft he ID at 4hpostinjection), the renal clearance of cysteine-coated AuNPs is not enhanced, and (220 AE 60) nm aggregates in phosphate-buffered saline and accumulation of the cysteine-coated AuNPs in the organs of the RES are observed. [56] To develop renal-clearable AuNPs,g reat efforts have been made by Zheng et al. by using zwitterionic glutathione (GSH, at ripeptide that is abundant in the cytoplasm and exhibits low affinity to plasma protein [66] )t om odify the surfaces of the particles and to minimize serum protein adsorption. [36, 56, 63, [67] [68] [69] The obtained GSH-coated AuNPs (GSAuNPs, Figure 8 ) can emit near-infraredl ight (core size:2 .5 nm, HD:3 .3 nm), have high resistance to PPB, and have high urinary recovery with more than 50 %o ft he ID at 48 hp ostinjection. Moreover,G SH can serve as au niversal surface chemistry to minimize nonspecific accumulation of inorganic NPs in the organs of the RES, as evidencedb yo ther GSH-coated ultrasmall metal NPs such as palladium nanoparticles (PdNPs) [54] and CuNPs [55] and their renal clearance. Besides GSH-coated AuNPs, renal-clearable AuNPs capped by otherz witterionic ligands such as dithiolated polyaminocarboxylate (DTDTPA) [57, 64] and dopamine sulfonate [53] are also prepared. Among zwitterionic-coated NPs, GS-AuNPs have been extensively investigated for biomedical imaginga nd diagnosis, ranging from tumor-targeting imaging to detection of kidney dysfunction.
On the one hand, GS-AuNPs with ac ore size of 2.5 nm and aH Do f3 .3 nm exhibit intrinsic NIR emission without conjugation of dyes and behave similarly to the small NIR dye IRDye800CW in terms of physiological stability and renal clearance. However,G S-AuNPs have enhanced permeability and ar etention effect because they have am uch longert umor retention time and faster normalt issue clearance than IRDye800CW.T hese merits enableG S-AuNPs to detect tumors with ah igher signal-to-noise ratio than IRDye800CW.G SAuNPs exhibit no severe accumulation in the organs of the RES and are desirable for cancerd iagnosis and therapy. [67] Additionally, NIR-emitting radioactiveGS-[
198 Au]AuNPs can be synthesized by incorporating ag old radioisotope, 198 Au. These GS-[ 198 Au]AuNPs retain the feature of renal clearance and display rapid in vivo kinetics that are comparable to those of smallmolecule contrast agentsu sed in the clinic. These GS-[ 198 Au]AuNPs are NIR-light emitters and are radioactive, and thus, they have potentiala pplications in dual-modality imaging. [68] On the other hand, noninvasive imagingo fk idney-clearance kinetics and stagingo fk idney dysfunction have been validated by using GS-AuNPs.Althought he endogenous GFR marker creatinine is routinelyu sed to assess overall kidney function and even to stage kidney dysfunction, it is considered as al ate indicator of kidney impairment, because it is often insensitivet o early-stage kidney dysfunction and can varyw ith anthropometric factors. [70] Furthermore, it is measurably abnormal only after significant GFR hasb een lost and cannot detect the region-specific injury.I nc onsequence, kidney impairment is usually detected at al ate stage and at herapeutic opportunity is generally lost. Therefore, more sensitivea gents to detect kidney dysfunction at an earlier stage are needed.
As mentioned above, conventionalf luorophores are generally rapidly and persistently accumulatedi ns kin tissues after intravenousi njection because of their high lipophilicity and accumulation in the lipid membranes of the skin. What is more, amphiphilic fluorescent NPs including QDs, [71] dye-coated SiNPs, [72] and nonluminescent plasmonic AuNPs [71] also exhibit high accumulation in the skin. Such ah igh accumulationo f agents in the skin is am ajor roadblock for the noninvasive imaging of kidney-clearance kinetics. Yu et al. have found that conventional organic fluorophores such as Cy3, Cy7, and IRDye800CW fail to enhancet he noninvasive kidney contrast and fluorescence imaging of kidney-clearance kinetics. [69] Luminescent inorganicN Ps can exhibit NIR emissions because of quantum-size effects. Unlike organic dyes, NIR-emitting GSAuNPs can basically enhancek idney contrast and extend the noninvasive detection time period. The percentage of kidneycontraste nhancement for GS-AuNPs can reach 90-150 %a t 12 min postinjection,a nd the value continuouslyi ncreases to am aximum value of (240 AE 55) %a t6 0min postinjection, which is roughly5 0times highert han that obtained for IRDye800CW at 60 min postinjection [(4.7 AE 0.8) %].Acontrast enhancemento f6 8% is observed even at 10 hp ostinjection of GS-AuNPs, and thus, the kidneys are still detectable after 10 h of intravenous injection. However,asimilar 68 %c ontrast enhancement is also the maximum value that IRDye800CW can reach at 0.6 min postinjection, which indicates that the detection time of GS-AuNPsi s1 000 times longert han that of IRDye800CW.T he remarkable improvement in kidney contrast and detection time is attributed to low accumulationo ft he hydrophilic GS-AuNPs in the skin and rapid clearance from the skin through the kidneys to the urine. The time-fluorescence intensity curves (TFICs) of the kidneys obtained from noninvasive and invasive detection in the same mousea fter GS-AuNPs injectiond emonstrate that no significant differences in decay half-life and percentage of relative renal function are observed between the two curves, andt he noninvasive kidney TFICs reflect the kidney clearance of the GS-AuNPs. These studies suggest that renal-clearable NIR-emitting GS-AuNPsa llow for the fluorescencei maging of kidney-clearance kinetics and have ah igh potential for the noninvasive stagingo fk idney dysfunction.
To validate NIR-emitting GS-AuNPs for stagingk idney dysfunction, the fundamental question of whether such fluorescence imaging techniques based on the use of GS-AuNPsa re sensitiveenough for the noninvasived ifferentiation of the various kidneyd ysfunction stages should be answered. To do this, Yu et al. have used aU UO mouse model. [69, 73] The UUO mouse model is aw ell-established preclinical model for ureteropelvic ChemistryOpen 2017, 6,456 -471 www.chemistryopen.org 2017 The Authors. Publishedb yWiley-VCH Verlag GmbH &Co. KGaA, Weinheim junction obstruction and is asymptomatic at an early stage but can causek idney impairmenti fn ot treated promptly. [74, 75] In the control (sham-operated) group, both the left andr ight ureters are not ligated. At 7-9 days postoperation, no significant differences in blood urea nitrogen and serum creatinine are observed between the UUO mice and the controlg roup. However,a lteredk idney structures caused by the obstruction are identified by ex vivo pathological analysis. These result suggest that both blood urea nitrogen and serum creatinine are not good indicators of kidney function in aU UO model,w hich is consistentw ith previous studies. [76] With the assistance of GSAuNPs by in vivo NIR fluorescence imaging, the UUO left kidney can be easily differentiated from the unobstructed kidneys by noninvasive imaging and analysis of the TFICs (Figure 9 ). The fluorescences ignals of the obstructed left kidney are dramatically reduced relative to those of the right kidney in UUO mice and those of both kidneys in the control group at 1min intravenous postinjection of GS-AuNPs ( Figure 9 ). [73] Such ad iminished accumulation of GS-AuNPs in the UUO kidneyi sa ttributed to dramatically reduced blood perfusion after obstruction. [77] However,I RDye800CW fails to distinguish so, because of its severe accumulationi nt he skin tissues.A side from the detection of kidneyi mpairment,t he stages of kidney dysfunction (mild kidney damage and severe kidney damage) can also be differentiated by noninvasive imagingo ft he kidney-clearance kinetics of GS-AuNPs. For kidneys with mild damage, the imaging peak value of the UUO left kidney is slightly reduced relative to that of the left kidney in control group, and the excretiono fG S-AuNPst hrough the kidneys in UUO mice is slowed down. For kidneys with severe damage, the imaging peak value dramatically decreases. These observations are in agreement with the data determined by SPECT imaging of UUO and pathological analysiso fk idney tissue; [73] for example, the renal tubulesh ave mild to moderate atrophy and dilatation is observed in kidneys with mild damage, whereas renal tubulard amage and cortical atrophy are much more pronouncedi nk idneys with severe damage. These resultsc learly indicatet hat fluorescencei maging of the kidney-clearance kineticso fG S-AuNPs can serve as an inexpensive and highly sensitive methodf or the noninvasive staging of kidney dysfunction in preclinical animal models.
Conclusions and Perspectives
Measurement of the glomerular filtrationr ate (GFR) on the basis of urinary or plasma clearance of either exogenous or endogenousf iltration agents is accepted as the gold-standard approachtoa ssess kidney function. However,iti snot routinely available, because the existing protocols are cumbersome, time consuming, and/or invasive. Significant development in the area of diagnosing kidney functiona nd disease is evident from the literature. We developed at ranscutaneous detection technique that allows the rapid and convenient determination of kidney functionw ithout the need for time-consuming blood/urine sample preparation.I mpressively,arecent study revealed that this noninvasive procedure for the measurement of kidney functioni nu nanesthetized animals did not negatively impact arterial pressure, heart rate, or locomotor activity. [78] Thus, it is crucial to avoid an anesthesia-related decrease in the GFR to acquire accurate results. Table 1p rovides ac ollection of representative fluorescent GFR agents that have been used to determine kidney function in preclinical studies. Especially, these zwitterionic near-infrared (NIR) agents we recently developed have ap ositive outlook by offeringadeeper penetration depth,a st he strongi ntrinsic background autofluorescence of living tissue is still one of the largesto bstacles during transcutaneous measurements. By taking advantages of the above NIR agentsa nd the transcutaneous detection technique, am uch more rapid, robust, and convenient approach for the noninvasive real-time assessment of kidney function is validated if compared to traditional GFR agents and determination methods. Nevertheless, further studies on the clearance and toxicityo ft hese GFR agentsi nl arger animalss uch as dogs or monkeys are neededb efore they can be really used in clinical practice.
Interestingly,s ome design strategies forf luorescent GFR agents are similart ot hose for inorganic renal-clearable nanoparticles (NPs);f or example, the use of either zwitterionic or neutralligands was shownf or the development of both organic GFR agents and inorganic renal-clearableN Ps. Therefore, we believe that using zwitterionic or neutral-charge characteristics is ac riticals trategy for the development of renal-clearable agents. Althoughanumber of renally clearable NPs have been developed to date (Table 2) , there are still many challenges and fundamentalq uestions that need to be addressed. For example,g lutathione-coated gold nanoparticles (GS-AuNPs) have been validated in differentiating the stages of kidney dysfunction;h owever,t he exact excretion mechanismso ft hese GSAuNPs from the kidney are not clear,a nd the question of whether secretion or reabsorption is involved in the process of Figure 9 . a) In the UUO mouse model, the left ureter of the mouse is completely ligated, whereas the right ureter is keptintact. In the control (shamoperated) group, the left ureters are exposed but not ligated. b) Representative whole-body noninvasive real-time fluorescence images (l ex /l em filters: 710/830 nm) of mice beforeand after intravenous injectionofG S-AuNPs at preinjection:1 ,5 ,1 0, and 60 min. Reprinted with permission from Ref. [69] . Copyright (2015)W iley-VCH. excretionn eeds furtheri nvestigation.T he low tissue penetration depth of light will remain ar oadblock for further application of these renal-clearable luminescent AuNPs in kidney functional imaging. One potentials olution is to combine it with other imaging modalities, such as positron emission tomography ands ingle-photon emission computed tomography imaging. Of note, carbon dots are the only renal-clearable inorganic NPs that have gained investigational new-drug approval by the Food andD rug Administration for first-in-human clinical trials. [79, 80] Therefore, whether other renal-clearable NPs are biocompatible enough for future applicationsi nh umans should be addressed.
Kidney disease has numerousc auses, including hypotension, trauma, acute tubular necrosis, urinary obstruction, and druginduced nephrotoxicity. [6] Although the GFR is considered the best indicator for overall kidney function, further efforts should be made towards the development of novel light-emitting agents for the detectiono fr egion-specific injury in kidneys (e.g. tubular necrosis and function) so that kidney diseases can be differentiated and that kidney injury can be diagnosed at an early stage.
